Acrux Ltd has released a press release.
Appendix 4E and Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Acrux
- Acrux receives third FDA ANDA approval
- Acrux Receives FDA Approval - Generic Efinaconazole Solution
- Acrux confirms patent challenge
- Acruxs fourth generic dossier accepted by FDA for review
- Acrux Investor Presentation
Later from Acrux
- US Launch - Testosterone Topical Solution
- Acrux Investor Presentation - September 2021
- Acruxs fifth generic dossier accepted by FDA for review
- Acrux and Harris terminate license agreement
- Appendix 4D, Half Year Accounts as at 31 December 2021
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux